Effectiveness of integrase strand transfer inhibitors in HIV‐infected treatment‐experienced individuals across Europe
Barbara Rossetti,Massimiliano Fabbiani,Domenico Di Carlo,Francesca Incardona,Ana B. Abecasis,Perpétua Gomes,Anna Maria Geretti,Carole Seguin-Devaux,Federico García,Rolf Kaiser,Sara Modica,Adrian Shallvari,Anders Sönnerborg,Maurizio Zazzi +13 more
TL;DR: To explore the effectiveness and durability of integrase strand transfer inhibitor (INSTI)‐based regimens in pre‐treated subjects, six subjects were treated with INSTI‐based chemotherapy and three subjects were not treated at all.
read more
Abstract: To explore the effectiveness and durability of integrase strand transfer inhibitor (INSTI)‐based regimens in pre‐treated subjects.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
TL;DR: Integrase strand transfer inhibitors (INSTIs) have improved the treatment of human immunodeficiency virus (HIV) by improving the genetic barrier to resistance, limited drugdrug interactions, excellent rates of virologic suppression, and favorable tolerability as mentioned in this paper .
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study
01 Apr 2023
TL;DR: In this paper , the authors aimed to project the health benefits and risks of pre-exposure prophylaxis (PrEP) introduction in settings in sub-Saharan Africa and compared outcomes for each with and without cabotegravir-PrEP introduction.
28
Modeling UNAIDS treatment targets for China
TL;DR: Blower et al. as discussed by the authors proposed a method for modeling the human brain using the Semel Institute for Neuroscience and Human Behavior (SENHBH) at the David Geffen School of Medicine at UCLA.
1
Applying Next-Generation Sequencing to Track HIV-1 Drug Resistance Mutations Circulating in Portugal
Victor Pimentel,Marta Pingarilho,Cruz S. Sebastião,Mafalda Miranda,Fátima Gonçalves,J. Cabañas,Inês Costa,Isabel Diogo,Sandra Fernandes,Olga Costa,Rita Corte-Real,Maria do Rosário de Oliveira Martins,Sofia G. Seabra,Ana B. Abecasis,Perpétua Gomes +14 more
TL;DR: Low levels of TDR to INSTIs among ART-naïve and moderate levels in ART-exposed patients are observed, presenting the first evidence on TDR and ADR to INSTI regimens in followed up patients presenting for healthcare in Portugal.
1
References
•Journal Article
R: A language and environment for statistical computing.
TL;DR: Copyright (©) 1999–2012 R Foundation for Statistical Computing; permission is granted to make and distribute verbatim copies of this manual provided the copyright notice and permission notice are preserved on all copies.
410.8K
Initiation of antiretroviral therapy in early asymptomatic HIV infection
Sean Emery,Shweta Sharma,Gerd Fätkenheuer,Josep M. Llibre,Jean-Michel Moli,Paula Munderi,Robin Wood,Karin L. Klingman,Simon Collins,H. Clifford Lane,Andrew N. Phil,James D. Neaton +11 more
TL;DR: The initiation of antiretroviral therapy in HIV-positive adults with a CD4+ count of more than 500 cells per cubic millimeter provided net benefits over starting such therapy in patients after the CD4+, but the risks of unscheduled hospital admissions were similar in the two groups.
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Christine Danel,Raoul Moh,Delphine Gabillard,Anani Badje,Le Carrou J,Ouassa T,Eric Ouattara,Anzian A,Jean-Baptiste Ntakpe,Albert Minga,Gérard-Menan Kouamé,Bouhoussou F,Emieme A,Abo Kouame,Inwoley A,Toni Td,Ahiboh H,Kabran M,Rabe C,Sidibé B,Nzunetu G,Konan R,Gnokoro J,Gouesse P,Messou E,Dohoun L,Kamagate S,Yao A,Amon S,Kouame Ab,Koua A,Kouamé E,Ndri Y,Ba-Gomis O,Daligou M,Ackoundzé S,Hawerlander D,Ani A,Dembélé F,Koné F,Guéhi C,Kanga C,Koule S,Séri J,Oyebi M,Mbakop N,Makaila O,Babatunde C,Babatounde N,Bleoué G,Tchoutedjem M,Kouadio Ac,Sena G,Yededji Sy,Assi R,Bakayoko A,Mahassadi A,Attia A,Oussou A,Mobio M,Bamba D,Koman M,Horo A,Nina Deschamps,Chenal H,Sassan-Morokro M,Konate S,Aka K,Aoussi E,Journot,Nchot C,Sophie Karcher,Chaix Ml,Christine Rouzioux,Sow Ps,Perronne C,Girard Pm,Menan H,Bissagnene E,Kadio A,Ettiegne-Traore,Moh-Semdé C,Massumbuko Jm,Chêne G,Dosso M,Domoua Sk,N'Dri-Yoman T,Roger Salamon,Serge-Paul Eholié,Xavier Anglaret +89 more
TL;DR: In this African country, immediate ART and 6 months of IPT independently led to lower rates of severe illness than did deferred ART and no IPT, both overall and among patients with CD4+ counts of at least 500 cells per cubic millimeter.
1.2K
Web resources for HIV type 1 genotypic-resistance test interpretation.
Tommy F. Liu,Robert W. Shafer +1 more
TL;DR: In this article, the authors describe the scientific principles of HIV-1 genotypic-drug-resistance test interpretation and the most commonly used Web-based resources for clinicians ordering GENotypic drug-resistant tests.
680
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Pedro Cahn,Anton Pozniak,Horacio Mingrone,Andrey Shuldyakov,Carlos Brites,Jaime Andrade-Villanueva,Gary Richmond,Carlos Beltran Buendia,Jan Fourie,Moti Ramgopal,Debbie Hagins,Franco Felizarta,José Valdez Madruga,Tania Reuter,Tamara Newman,Catherine B. Small,John Lombaard,Beatriz Grinsztejn,David Dorey,Mark R. Underwood,Sandy Griffith,Sherene Min +21 more
TL;DR: Once-daily dolutegravir, in combination with up to two other antiretroviral drugs, is well tolerated with greater virological effect compared with twice-daily raltegravIR in this treatment-experienced patient group.
518
Related Papers (5)
Sergio Serrano-Villar,Talia Sainz,Zhong-Min Ma,Netanya S. Utay,Tae Wook-Chun,Surinder K Mann,Angela D. M. Kashuba,Basile Siewe,Anthony Albanese,Paolo Troia-Cancio,Elizabeth Sinclair,Anoma Somasunderam,Tammy Yotter,Steven G. Deeks,Alan L. Landay,Richard B. Pollard,Christopher J. Miller,Christopher J. Miller,Santiago Moreno,David M. Asmuth +19 more